CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8) Applicant(s): **Andrews et al.**			Docket No. **PU4870USW**	
Application No. **10/522,958**	Filing Date **January 31, 2005**	Examiner	Customer No. **23347**	Group Art Unit **1614**

Invention: **Thiophene Compounds**

I hereby certify that this **Supplemental IDS w/accompanying papers**
(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on February 7, 2006.
(Date)

Valerie L. Phillips
(Typed or Printed Name of Person Mailing Correspondence)

Valerie L. Phillips
(Signature of Person Mailing Correspondence)

DOCKET No. PU48701USW Date Mailed 2/7/06 Atty/Secy LAM/VP

MAILING: CERTIFICATE/ EXPRESS MAIL # _____

U.S. Serial No. : 10/522,958 Filing Date: 1/31/05

Int'l App. No.: _____ Int'l Filing Date: _____

RECEIPT IS ACKNOWLEDGED FOR THE FOLLOWING:

- ☐ Appln Transmit +1 copy for: ☐ Provisional ☐ CIP
- ☐ Utility ☐ CONTIN ☐ DIV ☐ RCE
  - ☐ Specification _____ pgs ☐ Abstract ___ pgs
  - ☐ Decs ___ pgs ☐ Powers of Atty ___ pgs
- ☐ Drawings ____ Sheet(s)/Figs____ to ____
- ☐ Assignment ___ pgs & Recordation Cover Sheet
- ☐ Transmit Ltr Natl Stage Entry +fee pg (3pgs)
  - ☐ IPER ☐ SEARCH Rep. ☐ Pub-cover
- ☐ 2nd Transmit for Nat'l Stage
- ☒ Information Disclosure Statement Suppl.
- ☒ Form PTO-1449 5 pgs. ☒ 114 References
- ☐ Amendment ☐ Response _____ pgs
- ☐ Petition for____month Extension of Time +1 copy
- ☐ Issue Fee / Publication Fee (Part B) + 1 copy
- ☐ Copy of Notice to File Missing Parts
- ☐ Copy of Notice to Comply
- ☐ Statement to Support Filing
  - ☐ Diskette ☐ Sequence List
- ☐ Appeal Brief _____ pgs
- ☐ Petition __pgs
- ☐ PCT Request ☐ Fee Sheet
- ☐ PCT Power of Attorney
- ☐ PCT DEMAND
- ☐ Priority Doc #_____
- ☐ Notice of Appeal +fee
- ☐ Resp to Restrict Req __ pgs
- ☐ Req to Correct Filing Recpt w/copy
- ☐ Req for Cert of Correct _pgs
- ☒ Authorization to Charge Dep. Acct. # 07-1392
- ☐ Request for Nonpublication (1 pg)
- ☐ _____
- ☐ _____
- ☐ _____

PU4870USW

1614
DPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Andrews et al.	
Serial No.:	10/522,958	Group Art Unit: 1614
File Date:	January 31, 2005	Examiner:
For:	Thiophene Compounds	

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPL. INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references are enclosed: 21-134
[ ] Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
[ ] A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[ ] **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

B. [ ] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311, whichever occurs first.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) ($180.00).

C. [ ] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

[ ] The petition fee set forth in § 1.17(i)(1) ($130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.
[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan
Registration No. 38,181

Date: 7 Feb 2006

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/522,958
	FILING DATE	January 31, 2005
	APPLICANT	Andrews et al.
	GROUP	1614
	EXAMINER	
	ATTORNEY DOCKET NO.	PU4870USW

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	4,818,279	Apr. 4, 1989	Chaleat et al.			
	2	4,859,684	Aug. 22, 1989	Raeymaekers et al.			
	3	5,151,424	Sept. 29, 1992	Janssens et al.			
	4	5,342,957	Aug. 30, 1994	Van Wauwe et al.			
	5	5,420,147	May 30, 1995	Van Wauwe et al.			
	6	5,457,102	Oct. 10, 1995	Janssens et al.			
	7	5,491,161	Feb. 13, 1996	Janssens et al.			
	8	5,500,435	Mar. 19, 1996	Van Wauwe et al.			
	9	5,656,653	Aug. 12, 1997	Booher et al.			
	10	5,955,613	Sept. 21, 1999	Horvath et al.			
	11	5,990,146	Nov. 23, 1999	Boschelli et al.			
	12	6,114,327	Sept. 5, 2000	Dunlap et al.			
	13	6,133,282	Oct. 17, 2000	Horvath et al.			
	14	6,162,804	Dec. 19, 2000	Bilodeau et al.			
	15	6,180,380	Jan. 30, 2001	Strephardt et al.			
	16	6,218,388	Apr. 17, 2001	Boschelli et al.			
	17	6,310,079	Oct. 30, 2001	Okumura et al.			
	18	6,310,079	Oct. 30, 2001	Okumura et al.			
	19	6,358,738	Mar. 19, 2002	Erikson et al.			
	20	6,465,484	Oct. 15, 2002	Bilodeau et al.			

Continue on page ____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes | No
	21	EP 0111993	June 27, 1984	EUROPE			
	22	EP 0260744	Mar. 23, 1988	EUROPE			
	23	EP 0297661	June 23, 1988	EUROPE			
	24	EP 0563697	Oct. 6, 1993	EUROPE			
	25	EP 0563705	Oct. 6, 1993	EUROPE			X Abstract
	26	EP 0563714	Oct. 6, 1993	EUROPE			
	27	EP 0747363	Dec. 11, 1996	EUROPE			
	28	ES 547442	Sept. 30, 1985	SPAIN			X Abstract
	29	JP 2001 089368	Apr. 3, 2001	JAPAN			
	30	JP 63157157	June 30, 1988	JAPAN			
	31	JP2000095766	Apr. 4, 2000	JAPAN			
	32	WO 92/20642	Nov. 26, 1992	WIPO			
	33	WO 93/22314	Nov 11, 1993	WIPO			
	34	WO 95/16684	June 22, 1995	WIPO			
	35	WO 96/19991	July 4, 1996	WIPO			
	36	WO 97/46237	Dec. 11, 1997	WIPO			
	37	WO 98/45295	Oct. 15, 1998	WIPO			
	38	WO 98/47894	Oct. 29, 1998	WIPO			
	39	WO 98/49151	Nov. 5, 1998	WIPO			
	40	WO 02/062785	Aug. 15, 2003	WIPO			X Abstract
	41	WO 02/088107	Nov. 7, 2002	WIPO			X Abstract
	42	WO 04/014899	Feb. 19, 2004	WIPO			

Continue on page ____

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/522,958
	FILING DATE	January 31, 2005
	APPLICANT	Andrews et al.
	GROUP	1614
	EXAMINER	
	ATTORNEY DOCKET NO.	PU4870USW

		OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)
	43	"The General Strategy of the Cell Cycle." Chapter 17: The Cell-Division Cycle, pgs. 864-865.
	44	Abraham, R.T. "Phosphatidylinositol 3-Kinase Related Kinases." Current Opinion in Immunology, Vol. 8, 1996, pgs. 412-418.
	45	Alcalde, E., et al. Heterocyclic Betaines. Aza Analogues of Sesquifulvalene. 2. Azolium Azolate Inner Salts: Synthesis, Reactivity, and Structure of a 1:1 Adduct with Dimethyl Acetylenedicarboxylate." J. Org. Chem., Vol. 56, 1991, pgs. 4233-4238.
	46	Apen, P.G., et al. "Nucleophilic Aromatic Substitution in 4,5-Dicyanoimidazoles." Heterocycles, Vol. 29(7), 1989, pgs. 1325-1329.
	47	Arya, V.P., et al. "Synthesis of Nitroheterocycles: Part IV*-Syntheses of I-Substituted 4-Nitroisoquinolines, 5- & 6-Nitroindazoles & 6-Nitrobenzimidazole." "Indian Journal of Chemistry, Vol. 15B, July 1977, pgs 625-628.
	48	Ashby, M.N. "Caax Converting Enzymes." Current Opinion in Lipidology, Vol 9(2), Apr. 1998, pgs 99-102.
	49	Benassi, R., et al. "Conformational Properties of the Free and Methylated 2-Amino Group in Benzimidazole, Benzoxazole, and Benzothiazole. X-Ray Crystallographic Analysis and Nuclear Magnetic Resonance Study of the Internal Rotation." J. Chem. Soc. Perkin Trans. II 1985, pgs 1513-1521.
	50	Blythin, D.J., et al. "Antiinflammatory Activity of Substituted 6-Hydroxypyrimido[2,1-f]purine-2,4,8 (1H3H,9H)-triones. Atyptical Nonsteroidal Antiinflammatory Agents." J. Med. Chem., Vol. 29, 1986, pgs. 1099-1113.
	51	Brana, M.F., et al. "Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties of a New Series of Imidazonaphthalimides." J. Med. Chem., Vol. 45, 2002, pgs. 5813-5816.
	52	Brekken, R.A., et al. "Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice." Cancer Research, Vol. 60, Sept. 15, 2000, pgs 5117-5124.
	53	Brodt, P., et al. "Inhibition of the Type I Insulin-Like Growth Factor Receptor Expression and Signaling: Novel Strategies for Antimetastatic Therapy." Biochemical Pharmacology, Vol. 60, 2000, pgs. 1101-1107.
	54	Buckle, D.R., et al. "Novel 1H-Benzimidazol-4-ols with Potent 5-Lipoxygenase Inhibitory Activity." J. Med. Chem., Vol. 30, 1987, pgs 2216-2221.
	55	Canman, C.E., et al. "The Role of ATM in DNA Damage Responses and Cancer." Oncogene, Vol. 17, 1998, pgs 3301-3308.
	56	Chakrabarti, J.K., et al. "Heteroarene-fused Benzodiazepines. Part 1. Synthesis of Thieno-[2,3-b][1,5]-, -[3,2-b][1,5]-, and –[3,4-b][1,5]-benzodiazepinones." Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (9), 1978, pgs 937-941.
	57	Chu, K-Y, et al. "Colour and Constitution of the Nitro- and Dinitro-p-phenylenediamines and their N-Methyl Derivatives." J. Chem. Soc., Perkin Trans. 1, Vol. 10, 1978, pgs 1194-1198.
	58	Clews, J., et al. "The Synthesis of C_2-Symmetric and Axially Chiral Compounds for Recognition and Catalysis."Tetrahedron, Vol. 56, 2000, pgs. 8735-8746.
	59	Cooper, J.A. "Membrane-Associated Tyrosine Kinases as Molecular Switches." Cell Biology, Vol. 5, 1994, pgs. 377-387.
	60	Corral, C., et al. "Reactions of methyl 3-Hydroxythiophene-2-Carboxylate. Part 4. Synthesis of Methyl 5-Azolyl-3-Hydroxythiophene-2-Carboxylates." J. Heteracyclic Chem., Vol. 24, 1987, pgs 1301-1303.
	61	Corral, C., et al. "Reactions with 3-Hydroxy-2-methoxycarbonylthiophene; I. Synthesis of 3-Thienyloxyacetic Acid and its (Nuclear) Chloro and Bromo Derivatives." Synthesis, Oct. 1984, pgs. 847-850.
	62	Crank, G., et al. "Photochemistry of Heterocyclics. III Photolysis of Various 2-Substituted Benzimidazoles." Aust. J. Chem., Vol. 35, 1982, pgs 775-784.
	63	Donaldson, M.M. et al. "The Mitotic Roles of Polo-Like Kinase." Journal of Cell Science, Vol. 114(13), pgs. 2357-2358.
	64	Duggan, S.A., et al. "Crown-Linked Porphyrin Systems." J. Org. Chem., Vol. 66, 2001, pgs. 4419-4426.
	65	Fonseca, T., et al. "A Short Synthesis of Phenanthrol[2,3-d]imidazoles From Dehydroabietic Acid. Application of the Methodology as a Convenient Route to Benzimidazoles." Tetrahedron, Vol. 57, 2001, pgs 1793-1799.
	66	Franzen, R. "The Suzuki, the Heck, and the Stille Reaction – Three Versatile methods for the Introduction of New C-C Bonds on Solid Support." Can. J. Chem., Vol 78, 2000, pgs 957-962.
	67	Glover, D.M. et al. "Polo-Like Kinases: A Team That Plays Throughout Mitosis." Genes & Development, Vol. 12, 1998, pgs 3777-3787.

Continue on page 3

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/522,958
	FILING DATE	January 31, 2005
	APPLICANT	Andrews et al.
	GROUP	1614
	EXAMINER	
	ATTORNEY DOCKET NO.	PU4870USW

	68	Green, M.C., et al. "Monoclonal Antibody Therapy for Solid Tumors." Cancer Treatment Reviews, Vol. 26, 2000, pgs. 269-286.
	69	Hankovszky, H.O., et al. "Synthesis and Reaction of Ortho-Fluoronitroaryl Nitroxides. Novel Versatile Synthons and Reagents for Spin-Labelling Studies." Can. J. Chem., Vol. 67, 1989, pgs. 1392-1400.
	70	Hughes, D.L. "The Mitsunobu Reaction." Organic Reactions, Vol. 42, pgs. 335-656.
	71	Hundertmark, T., et al. "$Pd(PhCN)_2Cl_2/P(t\text{-}Bu)_3$: A Versatile Catalyst for Sonogashira Reactions of Aryl Bromides at Room Temperature." Organic Letters, Vol. 2(12), 2000, pgs 1729-1731.
	72	Hunter, T. "A Thousand and One Protein Kinases." Cell, Vol. 50, September 11, 1987, pgs 823-829.
	73	Iemura, R., et al. "Synthesis of 2-(4-Substituted-1-piperazinyl)benzimidazole as H1-Antihistaminic Agents." J. Med. Chem., Vol 29, 1985, pgs 1178-1183.
	74	Jackson, S.P. "DNA-Dependent Protein Kinase." Int. J. Biochem. Cell Biol., Vol 29(7), 1997, pgs. 935-938.
	75	Jiang, J.L. et al. "Novel Synthetic Method for Symmetric Diketones From Benzimidazolium Salts & BIS-Grignard Reagents." Synthetic Communications, Vol 28(22), 1998, pgs 4137-4142.
	76	Jung, F., et al. "Synthesis and Structure-Activity Relationship of New Cephalosporins with Amino Heterocycles at C-7. Dependence of the Antibacterial Spectrum and β–Lactamase Stability on the pK_a of the C-7 Heterocycles." J. Med. Chem., Vol. 34, 1991, pgs. 1110-1116.
	77	Kagechika, H., et al. "Retinobenzoic Acids. 1. Structure Activity Relationships of Aromatic Amides with Retinoidal Activity." J. Med. Chem., Vol. 31, 1988, pgs. 2182-2192.
	78	Kath, J.C. "Patent Focus: Inhibitors of Tumour Cell Growth." Exp. Opin. Ther. Patents, Vol. 10(6), 2000, pgs 803-818.
	79	Katsushima, T., et al. "Structure-Activity Relationships of 8-Cycloalkyl-1,3-dipropylxanthines as Antagonists of Adenosine Receptors." J. Med. Chem., Vol 33, 1990, pgs. 1906-1910.
	80	Kitada, S., et al. "Reversal of Chemoresistance of Lymphoma Cells by Antisense-mediated Reduction of bcl-2 Gene Expression." Antisense Research and Development 4, 1994, pgs 71-79.
	81	Lackey, K., et al. "The Discovery of Potent cRaf1 Kinase Inhibitors." Bioorganic & Medicinal Chemistry Letters, Vol. 10, 2000, pgs 223-226.
	82	Ladd, D.L., et al. "Synthesis and Tubulin Binding of 4'-(1-Azi-2,2,2-trifluoroethyl)Oncodazole, A Photolabile Analogue of Oncodazole." J. Org. Chem., Vol. 53, 1988, pgs 417-420.
	83	Larock, R.C. "3. Cyclic Sulfite, Sulfate and Thiocarbonate Substitution." Comprehensive Organic Transformations. Pgs. 972-987
	84	Lincoln, S.K., et al. "Synthesis, Structure, and Interconversion of Polypyrazolylborate Complex of Molybdenum(V)." Inorg. Chem., Vol. 25(10), 1986, PGS. 1594-1602.
	85	Littke, A.F., et al. "A Convenient and General Method for Pd-Catalyzed Suzuki Cross-Couplings of Aryl Chlorides and Arylboronic Acids." Angew. Chem. Ind. Ed. 1998, Vol. 37(24), pgs. 3387-3388.
	86	Littke, A.F., et al. "Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates Under Mild Conditions." J. Am. Chem. Soc., Vol 122, 2000, pgs. 4020-4028.
	87	Luker, T.J., et al. "Palladium Catalysed Amination of Electron Deficient Halothiophenes." Tetrahedron Letters, Vol 41, 2000, pgs 7731-7735.
	88	Martinez-Lacaci, I., et al. "RAS Transformation Causes Sustained Activators of Epidermal Growth Factor Receptor and Elevation of Mitogen-Activated Protein Kinase in Human Mammary Epithelial Cells." Int. J. Cancer, Vol. 88, 2000, pgs 44-52.
	89	Massaque, J., et al. "Serine/Threonine Kinase Receptors: Mediators of Transforming Growth Factor Beta Family Signals." Cancer Surveys, Vol. 27, 1996, pgs 41-64.
	90	Mertens, A., et al. "Nonsteroidal Cardiotonics. 1. 2-Pyridyl-6,7-Dihydro-3H,5H-Pyrrolo[2,3-f] Benzimidazol-6-Ones, A Novel Class of Cardiotonic Agents." J. Med. Chem., Vol. 30, 1987, pgs. 1279-1287.
	91	Mistry, A.G., et al. "A Superior Synthetic Method for the Bromination of Indoles and Benzimidazoles." Tetrahedron Letters, Vol 27(9), 1986, pgs 1051-1054.
	92	Mitsunobu, O. "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products." Synthesis, Jan. 1981, pgs. 1-28.
	93	Muller, S., et al. "An Improved One-Pot Procedure for the Synthesis of Alkynes From Aldehydes." Synlett, June 1996, pgs 521-522.
	94	Nagaraja, D., et al. "Reduction of Aryl Nitro Compounds With Aluminum/NH_4Cl : Effect of Ultrasound on the Rate of the Reaction." Tetrahedron Letters, Vol. 40, 1999, pgs. 7855-7856.
	95	Nahm, S., et al. "N-Methoxy-N-Methylamides As Effective Acylating Agents." Tetrahedron Letters, Vol. 22(39), 1981, pgs. 3815-3818.

Continue on page 4

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/522,958
		FILING DATE	January 31, 2005
		APPLICANT	Andrews et al.
		GROUP	1614
		EXAMINER	
		ATTORNEY DOCKET NO.	PU4870USW

	96	Nasielski-Hinkens, R. et al. "The Four 6-Halo-7-Nitroquinoxalines." Heterocycles, Vol. 26, 1987, pgs 2433-2442.
	97	Negishi, E. "Novel and Selective α-Substitution of Ketones and Other Carbonyl Compounds Based on Pd-Catalyzed Cross Coupling of αβ- Unsaturated Carbonyl Derivatives Containing α-Halogen or α-Metal Groups." Journal of Organometallic Chemistry, Vol. 576, 1999, pgs 179-194.
	98	Oliff, A. Garnesyltransferase Inhibitors: Targeting the Molecular Basis of Cancer." Biochimica et Biophysica Acta, Vol. 1423, 1999, pgs C19-C30.
	99	Palmer, B.D., et al. "Structure-Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor." J. Med. Chem., Vol. 41, 1998, pgs 5457-5465.
	100	Penieres, G.C., et al. "Synthesis of Benzimidazoles in Dry Medium." Synthetic Communications, Vol. 30(12), 2000, pgs. 2191-2195.
	101	Philip, P.A., et al. "1. Potential for Protein Kinase C Inhibitors in Cancer Therapy." F.M. Muggia (ed), Concepts, Mechanisms, and New Targets for Chemotherapy. Kluwer Academic Publishers, Boston, pgs.3-27.
	102	Raban, M., et al. "N-(Arylthio)benzimidazoles. Torsional Barriers and 1,3 Rearrangement." The Journal of Organic Chemistry, Vol. 50(13), June 28, 1985, pgs. 2210-2216.
	103	Rangarajan, M., et al. "Topoisomerase I Inhibition and Cytotoxicity of 5-Bromo- and 5-Phenylterbenzimidazoles." Bioorganic & Medicinal Chemistry, Vol. 8, 2000, pgs. 2591-2600.
	104	Rosania, G.R., et al. "Targeting Hyperproliferative Disorders with Cyclin Dependent Kinase Inhibitors." Expert Opinion on Therapeutic Patents, Vol.10(2), 2000, pgs. 215-230.
	105	Scharovsky, O.G., et al. "Inhibition of rasOncogene: A Novel Approach to Antineoplastic Therapy." J. Biomed. Sci., Vol 7, 2000, pgs 292-298.
	106	Schlessinger, J., et al. "Growth Factor Signaling by Receptor Tyrosine Kinases." Neuron, Vol. 9, September, 1992, pgs 383-391.
	107	Sharma, K.S., et al. "Condensed Heterocycles; XI. Synthesis of 1,2,5-Thia(selena)diazolo[3,4-b]quinolines and 1,2,5-Thia(selena)diazolo[3,4-h)quinolines." Synthesis, Apr. 1981, pgs. 316-318.
	108	Shawver, L.K., et al. "Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis." DDT, Vol. 2(2), Feb. 1997, pgs 50-63.
	109	Silvestri, R., et al. "Computer-Assisted Design, Synthesis and Biological Evaluation of Novel Pyrrolyl Heteroaryl Sulfones Targeted at HIV-1 Reverse Transcriptase as Non-Nucleoside Inhibitors." Bioorganic & Medicinal Chemistry, Vol. 8, 2000, pgs. 2305-2309.
	110	Sinha, S., et al. "State-of-the-Art Review, Implications of Src Kinases in Hematopoiesis: Signal Transduction Therapeutics." Journal of hematotherapy & Stem Cell Research, Vol. 8, 1999, pgs 465-480.
	111	Smithgall, T.E. "SH2 and SH3 Domains: Potential Targets for Anti-Cancer Drug Design." Journal of Pharmacological & Toxicological Methods, Vol. 34, 1995, pgs 125-132.
	112	Srivastava, R.P., et al. "Synthesis of 2,5-Disubstituted Benzimidazoles, 1,3,4-Thiadiazoles and 3,5-Diiodosalicylanilides as Structural Congeners of Rafoxanide and Closantel." Pharmazie, Vol. 45, 1990, pgs. 34-37.
	113	Stanforth, S.P. "Catalytic Cross-Coupling Reactions in Biaryl Synthesis." Tetrahedron, Vol. 54, 1998, pgs. 263-303.
	114	Stern, D.F. "Tyrosine Kinase Signalling in Breast Cancer ErbB Family Receptor Tyrosine Kinases." Breast Cancer Res. 2, 2000, pgs 176-183.
	115	Suzuki, A. "Recent Advances in the Cross-Coupling Reactions of Organoboron Derivatives with Organic Electrophiles, 1995-1998." Journal of Organometallic Chemistry, Vol. 576, 1999, pgs. 147-168.
	116	Tamura, S.Y. et al. "Rational Design, Synthesis, and Serine Protease Inhibitory Activity of Novel P_1-Argininoyl Heterocycles. Bioorganic & Medicinal Chemistry Letters, Vol. 7(10), 1997, pgs. 1359-1364.
	117	Tanaka, A., et al. "Studies on Anti-platelet Agents. II. Synthesis and Platelet-Inhibitory Activity of 5-Methyl-4-(3-pyridyl)-2-(substituted Benzimidazol-5-yl)imidazoles." Chem. Pharm. Bull., Vol 42(3), 1994, pgs 560-569.
	118	Taylor, E.C., et al. "Synthesis of [4-(2-Guanin-8-ylethyl)benzoyl]glutamic Acid, A Guanine Analogue of DDATHF." J. Org. Chem., Vol. 56, 1991, pgs. 6937-6939.
	119	Thorand, S., et al. "Improved Procedures for the Palladium-Catalyzed Coupling of Terminal Alkynes with Aryl Bromides (Sonogashira Coupling)." J. Org. Chem., Vol. 63, 1998, pgs. 8551-8553.
	120	Tian, W., et al. "A Useful Methodology for the Synthesis of 2-Methyl-4-Nitrobenzimidazoles." Synthesis, Dec. 1992, pgs 1283-1286.

Continue on page 5

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/522,958
		FILING DATE	January 31, 2005
		APPLICANT	Andrews et al.
		GROUP	1614
		EXAMINER	
		ATTORNEY DOCKET NO.	PU4870USW

	121	Tyle, P. "Iontophoretic Devices for Drug Delivery." Pharmaceutical Research, Vol. 3(6), 1986, pgs. 318-326.
	122	Ullrich, A., et al. "Signal Transduction by Receptors with Tyrosine Kinase Activity." Cell, Vol. 61, Apr. 20, 1990, pgs.203-212.
	123	Von Boehmer, H., et al. "Structure and Function of the Pre-T Cell Receptor." Annu. Rev. Immunol., Vol. 15, 1997, pgs 433-452.
	124	von der Saal, W., et al. "Nonsteroidal Cardiotonics. 2. The Inotropic Activity of Linear, Tricyclic 5-6-6 Fused Heterocycles." J. Med. Chem., Vol. 32, 1989, pgs 1481-1491.
	125	Waters, J.S., et al. "Phase I Clinical and Pharmacokinetic Study of Bel-2 Antisense Oligonucleotide Therapy in Patients with Non-Hodgkin's Lymphoma." J. of Clin. Oncology, Vol. 18(9), May 2000, pgs 1812-1823.
	126	White, A.W., et al. "Resistance-Modifying Agents. 9.1 Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) ." J. Med. Chem., Vol. 43, 2000, pgs 4084-4097.
	127	Wilks, A.F. "Structure and Function of the Protein Tyrosine Kinases." Progress in Growth Factor Research, Vol. 2, 1990, pgs 97-111.
	128	Wissner, A., et al. "Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)." J. Med. Chem., Vol. 46, 2003, pgs. 49-63.
	129	Wolfe, J.P., et al. "Rational Development of Practical Catalysts for Aromatic Carbon-Nitrogen Bond Formation." Acc. Chem. Res., Vol. 31, 1998, pgs. 805-818.
	130	Wright, J.L., et al. "Subtype-Selective N-Methyl-D-Aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Heteroarylalkynyl)-4-Benzylpiperidines." J. Med. Chem., Vol. 43, 2000, pgs. 3408-3419.
	131	Yamamoto, T., et al. "Ras-Induced Transformation and Signaling Pathway." J. Biochem., Vol. 126, 1999, pgs. 799-803.
	132	Yin, J., et al. "Palladium-Catalyzed Intermolecular Coupling of Aryl Halides and Amides." Organic Letters, Vol 2(8), 2000, pgs 1101-1104.
	133	Young, R.C., et al. "Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatidylinositol 4-Kinase." J. Med. Chem. Vol. 33, 1990, pgs 2073-2080.
	134	Zhong, H., et al. "Modulation of Hypoxia-Inducible Factor 1α Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics." Cancer Research, Vol. 60, March 15, 2000, pgs. 1541-1545.

Continue on page ___

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.